QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Northwest Biotherapeutics, Inc. (NWBO) Receives $5.5M Grant To Cover Manufacturing And Clinical Trial Costs 1 comment
    May 1, 2012 5:27 PM | about stocks: NWBO

    Northwest Biotherapeutics, a biotech company focused on developing improved immunotherapy products to treat cancers, today announced that, working together with the Fraunhofer Institute (IZI), it has received approval of a $5.5 million grant from the Sachsische Aufbau Bank (SAB or Saxony Development Bank) in Germany. Funding for the grant has been provided by the German Federal State of Saxony and the European Union.

    The grant will reimburse 50 percent of the manufacturing costs in Germany, as well as for NW Bio's clinical trial with DCVax®-L for brain cancer at up to 30 clinical sites in Germany.

    NW Bio said it has made a strategic decision to settle in Leipzig, Germany, in the State of Saxony, and will establish its subsidiary there. Leipzig is also home to Fraunhofer Institute IZI, and is an ideal location for the entities because of the state's concentrated focus on regenerative medicine and cell therapies (including immune therapies).

    Backed by the support of the State of Saxony, NW Bio said it plans to expand its development and long-term marketing activities for DCVax®-L in Europe. The German clinical sites will also provide domestic data for EU approval processes.

    "After working closely for more than seven months on this grant application process with partners at Fraunhofer IZI, Bioville GmbH, the Translational Center for Regenerative Medicine and Cognate GmbH, we are excited and honored to be awarded one of the largest such R&D grants ever made by the Saxony Development Bank," Linda Powers, CEO of NW Bio stated in the press release. "This award will help us build our base in Germany, and accelerate our brain cancer clinical trial in Europe as well as the US, with some of the most respected institutions on both sides of the Atlantic."

    For more information visit nwbio.com

    About QualityStocks

    QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

    Sign up for "The QualityStocks Daily Newsletter" at QualityStocks.net

    The Quality Stocks Daily Blog blog.qualitystocks.net

    The Quality Stocks Daily Videos videocharts.qualitystocks.net

    The Quality Stocks "Ones to Watch" gotstocks.qualitystocks.net

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: NWBO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • aleanto
    , contributor
    Comment (1) | Send Message
    anybody has any news about NWBO?? The stock its so quiet maybe something big its coming !!
    12 Jul 2012, 02:54 PM Reply Like
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.